Next Article in Journal
Rebuilding the Strain Hardening at a Large Strain in Twinned Au Nanowires
Next Article in Special Issue
Nano-Mediated Photodynamic Therapy for Cancer: Enhancement of Cancer Specificity and Therapeutic Effects
Previous Article in Journal
Physicochemical Characterization of FRET-Labelled Chitosan Nanocapsules and Model Degradation Studies
Previous Article in Special Issue
Evaluating Nanoshells and a Potent Biladiene Photosensitizer for Dual Photothermal and Photodynamic Therapy of Triple Negative Breast Cancer Cells
Open AccessArticle

Temoporfin-in-Cyclodextrin-in-Liposome—A New Approach for Anticancer Drug Delivery: The Optimization of Composition

1
Centre de Recherche en Automatique de Nancy, Centre National de la Recherche Scientifique UMR 7039, Université de Lorraine, Campus Sciences, Boulevard des Aiguillette, 54506 Vandoeuvre-lès-Nancy, France
2
Research Department, Institut de Cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519 Vandoeuvre-lès-Nancy, France
3
Laboratory of Biophysics and Biotechnology, Belarusian State University, 4 Nezavisimosti Avenue, 220030 Minsk, Belarus
4
Biolitec Research GmbH, Otto-Schott-Strasse 15, 07745 Jena, Germany
5
International Sakharov Environmental Institute, Belarusian State University, Dauhabrodskaja 23, 220030 Minsk, Belarus
*
Author to whom correspondence should be addressed.
Nanomaterials 2018, 8(10), 847; https://doi.org/10.3390/nano8100847
Received: 12 September 2018 / Revised: 3 October 2018 / Accepted: 16 October 2018 / Published: 18 October 2018
(This article belongs to the Special Issue Nanomaterials for Photothermal/Photodynamic Therapy)
The main goal of this study was to use hybrid delivery system for effective transportation of temoporfin (meta-tetrakis(3-hydroxyphenyl)chlorin, mTHPC) to target tissue. We suggested to couple two independent delivery systems (liposomes and inclusion complexes) to achieve drug-in-cyclodextrin-in-liposome (DCL) nanoconstructs. We further optimized the composition of DCLs, aiming to alter in a more favorable way a distribution of temoporfin in tumor tissue. We have prepared DCLs with different compositions varying the concentration of mTHPC and the type of β-cyclodextrin (β-CD) derivatives (Hydroxypropyl-, Methyl- and Trimethyl-β-CD). DCLs were prepared by thin-hydration technique and mTHPC/β-CD complexes were added at hydration step. The size was about 135 nm with the surface charge of (−38 mV). We have demonstrated that DCLs are stable and almost all mTHPC is bound to β-CDs in the inner aqueous liposome core. Among all tested DCLs, trimethyl-β-CD-based DCL demonstrated a homogenous accumulation of mTHPC across tumor spheroid volume, thus supposing optimal mTHPC distribution. View Full-Text
Keywords: temoporfin; drug-in-cyclodextrin-in-liposome; nanoparticles; multicellular tumor spheroids; flow cytometry; photodynamic therapy temoporfin; drug-in-cyclodextrin-in-liposome; nanoparticles; multicellular tumor spheroids; flow cytometry; photodynamic therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Yakavets, I.; Lassalle, H.-P.; Scheglmann, D.; Wiehe, A.; Zorin, V.; Bezdetnaya, L. Temoporfin-in-Cyclodextrin-in-Liposome—A New Approach for Anticancer Drug Delivery: The Optimization of Composition. Nanomaterials 2018, 8, 847.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop